Skip to content

Update on progress for drug development programs VP01 (C21) and VP02 (IMiD)

Gothenburg, December 18, 2019 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces an update with regards to its clinical lead program VP01 (C21) and the second program VP02 (IMiD).

The phase II clinical study with C21 in patients with systemic sclerosis (SSc) started to recruit patients in December according to plan, and Vicore expects the study to be completed within a year. The study is designed to study the effect of C21 on cold induced vasoconstriction in patients with SSc.

“This study will shed light on the role of the AT2 receptor’s role and potential effect in improving blood flow in diseased tissues, an effect that may benefit patients with SSc as well as patients with idiopathic pulmonary fibrosis (IPF)” says Carl-Johan Dalsgaard, CEO of Vicore.

The second phase II trial, addressing the effects of C21 on patients with IPF, is currently subject to design improvements after positive interactions with the UK regulatory agency and subsequent iterations with the company’s clinical experts. The new design will aim to allow for a faster recruitment of patients and a more solid information package.

“It is our ambition to conduct the best possible study to answer the question if C21 can preserve lung function in patients with IPF” says Carl-Johan Dalsgaard. The clinical trial application will be filed early next year.

The VP02 program, which relates to local lung delivery of an IMiD to patients with IPF and IPF cough, is progressing according to plan and a product candidate showing promising separation between local and systemic exposure is being progressed into toxicology studies.

For further information, please contact:

Carl-Johan Dalsgaard, CEO, tel: +46 70 975 98 63,


Source: Vicore Pharma